The gastrointestinal tract is lined by a single cell layer of epithelium in which adjacent cells are joined together at their apical poles by tight junctions. This epithelial lining performs a critical barrier function to limit uptake of luminal antigens and noxious substances into the body. Epithelial permeability is increased in a number of enteropathies, such as inflammatory bowel disease, coeliac disease, and food allergies (reviewed by Bjarnason and colleagues, 1 Meddings, 2 and Sartor 3 ). Indeed, it has been suggested that a primary defect in the barrier function of the gastrointestinal epithelial layer may be a predisposing factor in the pathogenesis of Crohn's disease. 4 Although this hypothesis remains to be confirmed, it is likely that excessive uptake of luminal antigens and/or bacterial products into the mucosa may trigger inflammatory reactions with release of cytokines and bioactive mediators resulting in intestinal damage and dysfunction.
Animal models and epithelial cell culture studies have demonstrated that many factors are capable of increasing intestinal epithelial permeability. Such factors include the nutritional status of the host, 5 certain medications, 6 stress, 7 bacterial infections and/or toxins, [8] [9] [10] and immune cell cytokines (for example interferon , 11 tumour necrosis factor , 12 13 and interleukin 4 14 15 ). Although it is clear that a number of stimuli can elicit greater gastrointestinal permeability, less is known about factors that maintain or enhance the barrier function of the intestinal epithelium. Growth factors, including transforming growth factor , 16 17 insulin-like growth factor-1, 18 and epidermal growth factor 19 20 are capable of maintaining or restoring intestinal mucosal integrity thereby fostering healing and restitution. However, most growth factors are not organ specific and induce additional non-specific changes that can aVect homeostasis.
In 1971, Gleeson et al described a glucagon secreting endocrine tumour capable of inducing intestinal hyperplasia. 21 More recent investigations have shown that a cleavage product of the molecule, designated glucagon-like peptide-2 (GLP-2), is a trophic factor specific for the bowel. Thus in mice, twice daily treatment with low doses of GLP-2 resulted in increased gut weight and villus height in the small intestine but did not aVect the thickness of the smooth muscle layer. 22 Concomitant with the change in gut architecture was an increase in disaccharidase levels and increased nutrient absorption. 23 Despite the recognition that GLP-2 stimulates small intestinal growth, the relationship between this novel growth factor and intestinal barrier function has not been reported. Therefore, the primary aim of this study was to determine the ability of GLP-2 and a protease resistant analogue to regulate the barrier function of the murine small intestine. Our data illustrate that GLP-2 significantly reduces paracellular transport of ions and small molecules, and moreover dramatically inhibits endocytic uptake of macromolecules. These findings support the postulate that GLP-2 treatment may be an eVective therapy for Abbreviations used in this paper: GLP-2, glucagon-like peptide-2; HRP, horseradish peroxidase; Isc, short circuit current; PBS, phosphate buVered saline. 2 This dose was chosen based on pilot studies with native GLP-2 which showed that it produced consistent, significantly increased mucosal growth. Controls were injected with the vehicle (phosphate buVered saline (PBS)). Experiments were conducted on day 11 when mice were weighed and sacrificed by cervical dislocation. The small intestine was removed, flushed with cold saline, blot dried, and weighed. The jejunum was divided into segments for morphometric assessment, protein determination, and Ussing chamber studies. To obtain information on the timing of eVects, additional experiments were conducted in mice injected once with h[Gly 2 ]GLP-2 and studied at four hours and in mice injected twice a day for two days and studied at 48 hours. The studies described in this paper were conducted with approval from the McMaster University Animal Care Committee.
MORPHOLOGY
Light microscopy A 1 cm segment of intestine (∼10 cm from the pylorus) was opened along the mesenteric border and immersion flat fixed in 10% neutral buVered formalin. After dehydration and wax embedding, tissue sections were stained with haematoxylin and eosin. Mucosal height, villus length, and crypt depth were measured in coded sections (8-10 intact villus-crypt units per mouse) by a single investigator (MAB), who was unaware of the mouse treatment, using a calibrated eyepiece. The villus:crypt ratio was subsequently calculated.
Electron microscopy
An additional 1 cm segment (distal to that taken for light microscopy) was immediately fixed with 2% glutaraldehyde in 0.1 mol/l sodium cacodylate buVer for two hours at room temperature, transferred to sodium cacodylate buVer, and stored at 4°C overnight. Tissues were subsequently processed for routine electron microscopy. Photomicrographs of well orientated epithelial cells from the mid villus region were prepared. Using a computer supported image analysis system (Mop Videoplan, Kontron, Germany) one investigator (PCY), who was unaware of the mouse treatment, analysed 12 coded photomicrographs per group and measured enterocyte width and length, and microvillus length.
MUCOSAL PROTEIN
A 7 cm segment of small intestine (proximal to that used for morphology) was removed and the mucosal layer was scraped oV between two glass slides. The mucosal scraping was weighed and buVer was added at a concentration of 10 ml/g tissue. The mucosal suspension was homogenised on ice for 30 seconds, snap frozen in liquid nitrogen, and stored at −20°C before determination of protein content. 24 
USSING CHAMBER STUDIES
A 12 cm segment of small intestine (distal to that used for morphology) was opened along the mesenteric border and cut into four flat sheets. Full thickness segments (devoid of Peyer's patches) were mounted in modified Ussing chambers and bathed with oxygenated Krebs buVer that contained (in mM): 115 NaCl, 1.25 CaCl 2 , 1.2 MgCl 2 , 2.0 KH 2 PO 4 , and 25 NaHCO 3 , pH 7.35±0.02, at 37°C. In addition, the serosal buVer contained 10 mM glucose as an energy source balanced by 10 mM mannitol in the mucosal buVer. Glucose was not added to the mucosal buVer as we were interested specifically in permeability rather than glucose linked ion transport. Tissues were short circuited at zero volts using a World Precision Instruments automated voltage clamp (Narco Scientific, Mississauga, Ontario, Canada). 25 Conductance (G) was calculated according to Ohm's law using potential diVerence and short circuit current (Isc) values. Tissues with abnormally high initial conductance values (>40 mS/cm 2 ) or whose conductance increased during the course of the experiment (calculated every 15 minutes) were considered damaged and were excluded from subsequent analysis.
(a) Flux of Na

+
The unidirectional serosal-to-mucosal flux of Na + was determined as an indication of passive ion permeability via the paracellular pathway. Flux was measured under voltage clamped conditions by adding 10 µCi of 22 
Na
+ (New England Nuclear, Lachine, Quebec, Canada) to the serosal buVer. Following a 20 minute equilibration period, 1 ml samples from the "cold" buVer and 50 µl samples from the "hot" buVer were collected and replaced with the appropriate volume of buVer every 15 minutes. Radioactivity was measured in a gamma counter and flux (in µmol/cm 2 /h) was calculated.
(b) Flux of Cr-EDTA
Cr-EDTA is generally considered to be a marker of paracellular permeability. 1 Transepithelial flux of this small (360 Da) inert probe was determined as described previously 13 using the same approach as that for the radiolabelled ion. 51 Cr-EDTA (6 µCi/ml; Radiopharmacy, Chedoke-McMaster Hospital, Hamilton, Ontario, Canada) was added to the mucosal buVer bathing jejunal segments mounted in Ussing chambers. Non-radioactive Cr-EDTA was added to the serosal buVer at an equal concentration. Samples were obtained as above, counted, and flux expressed in nmol/cm 2 /h.
(c) Flux of horseradish peroxidase (HRP)
The transcellular passage of HRP (44 000 Da), a model protein antigen, 25 was determined by flux and electron microscopy (see below) as previously described. 26 Type VI HRP (SigmaAldrich Canada Inc., Oakville, Ontario, Canada) was added to the mucosal buVer at a concentration of 10 −5 M. Samples were obtained at intervals as above. The sample (appropriately diluted) was then mixed with a reaction solution containing hydrogen peroxide and o-dianisidine (Sigma-Aldrich Canada Inc.), and the rate of appearance of the reaction product was determined at 460 . Flux was expressed as pmol/cm 2 /h.
(d) Quantification of HRP containing endosomes in enterocytes.
Following exposure of the intestine in Ussing chambers to luminal HRP for 60 minutes, the segment was removed and immersed in 2% glutaraldehyde in 0.1 mol/l sodium cacodylate buVer for two hours at room temperature, transferred to sodium cacodylate buVer, and stored at 4°C overnight. The tissue was washed three times in 0.05 mol/l Tris buVer and then incubated for 30 minutes in 5 mg of 3,3'-diaminobenzadine tetrahydrochlorine (SigmaAldrich Canada Inc.) in 10 ml of 0.05 mol/l Tris buVer and 0.01% hydrogen peroxide. The tissue was subsequently processed for electron microscopy and photomicrographs prepared of well oriented epithelial cells. The area occupied by HRP product containing endosomes located within a 112 µm 2 window in the apical region of the enterocyte above the nucleus was measured in coded photomicrographs by one of the investigators (PCY) using a computer supported image analysis system. A total of 12 windows for each of four mice per group (48 enterocytes) were analysed.
(e) EVect of in vitro addition of GLP-2.
GLP-2 (5-1000 nM) was added to the luminal or serosal side of intestinal segments from naïve mice and G and Isc values were monitored over a 90 minute period.
STATISTICAL ANALYSES
Statistical analyses were performed using one way analysis of variance followed by NewmanKeuls multiple comparisons test. Student's t test was used for individual comparisons. Data are expressed as mean (SEM). 
Results
INTESTINAL CHARACTERISTICS
Weight and protein
(A) EVect of GLP-2 or h[Gly 2 ]GLP-2 treatment (5 µg injected on each of 10 days in mice) on wet weight of the small intestine or small intestinal weight as a percentage of body weight. (B) EVect of GLP-2 or
Figure 2 Representative photomicrographs of murine intestinal enterocytes. (A) and (C) are from phosphate buVered saline (PBS) treated mice (control); (B) and (D) are from mice after 10 days of treatment with h[Gly 2 ]GLP-2 (5 µg). Note the longer microvilli in h[Gly 2 ]GLP-2 treated mice (B) compared with controls (A) (bar=200 µm). The arrowhead in (B) indicates an endosome containing HRP. Note the increased cell length in h[Gly 2 ]GLP-2 treated mice (D) compared with controls (C) (bar=100 µm
Figure 3 EVect of GLP-2 or h[Gly 2 ]GLP-2 treatment (5 µg injected on each of 10 days in mice) on (A) transepithelial ion conductance and (B) flux of 51 Cr-EDTA across jejunal segments. Values are mean (SEM). (A) n=30-31 tissues from eight mice per group. (B) n=14-16 tissues from four mice per group.*p<0.05 compared with control (phosphate buVered saline (PBS) treated mice);
†p<0.05 compared with GLP-2 treated mice. (table  3) . However, epithelial cells and microvilli were longer at 48 hours (but not at four hours), with cell length similar to that after 10 days of treatment. In contrast, tissue conductance was significantly reduced (p<0.05) at both four and 48 hours, and the flux of Cr-EDTA was also significantly decreased (p<0.05) from 15.5 (1.1) (n=33) to 10.2 (0.4) (n=13) and 11.7 (0.8) (n=11) µmol/h/cm 2 (table 3) . Furthermore, the flux of the macromolecule HRP was even more dramatically diminished (p<0.01) even by four hours (to 1.6 (0.2) from 3.8 (0.5) pmol/h/cm 2 ).
Figure 4 EVect of GLP-2 or h[Gly 2 ]GLP-2 treatment (5 µg injected on each of 10 days in mice) on macromolecular permeability measurements following luminal addition of horseradish peroxidase (HRP 10 −5 mol/l). (A) Flux of HRP across jejunal segments. Values are mean (SEM); n=12-15 tissues from 4-5 mice per group.*p<0.05 compared with control mice. (B) Area of HRP containing endosomes in enterocytes 60 minutes after HRP addition. Values are mean (SEM); n=12 photomicrographs per mouse, four mice per group (48 enterocytes). ***p<0.001 compared with control (phosphate buVered saline (PBS) treated mice); †p<0.05 compared with GLP-2 treated mice.
Discussion
Unimpeded entry of antigen into the mucosa can result in an inflammatory or immune cascade that culminates in major tissue damage and functional abnormalities. The epithelial lining of the intestine eVectively acts as a regulated physiological sieve, maintaining the integrity of the barrier, and thereby acting as a first line of defence. In the present study we demonstrated for the first time that GLP-2 and a dipeptidyl peptidase IV resistant GLP-2 analogue, h[Gly 2 ]GLP-2, significantly enhanced the barrier property of normal murine small intestine.
Early clinical observations 21 and animal studies 22 suggested that an enteric form of glucagon (enteroglucagon) exerted a growth promoting influence on the mammalian intestine. In the gut, the proglucagon peptide can be cleaved into glicentin, oxyntomodulin, GLP-1, and GLP-2. GLP-2 is a 33 amino acid peptide that is generated in enteroendocrine L cells in the gut and whose sequence is highly conserved across mammalian species. 22 This peptide has been found to increase murine total gut weight and elicit villus elongation. 22 Tsai et al observed that GLP-2 did not stimulate intestinal proliferation via an eVect on food consumption. 27 Subsequent studies by the same workers showed that the intestinotrophic eVect of GLP-2 was not gender or strain specific and was most eVective when administered subcutaneously twice daily for 10 consecutive days. 27 28 The increased intestinal mucosal mass was correlated with an increase in crypt cell proliferation and reduced numbers of apoptotic cells. These observations imply that GLP-2 may directly or indirectly modulate the primary functions of the intestinal epitheliumthat is, selective transport and permeability. For instance, GLP-2 treated mice showed increased total expression of the disaccharidases maltase, sucrase, and lactase. 23 In addition, acute (0.5-4 hours) low dose (pmolnmol) GLP-2 administered to rats by intravenous infusion increased glucose transport via GLUT2 in small intestinal basolateral membrane vesicles 29 and via SGLT-1 in brush border membrane vesicles. 30 Although data are accumulating on the eVects of GLP-2 on intestinal nutrient transport, there is a paucity of information on the role of GLP-2 in the modulation of intestinal permeability.
Before consideration of the putative ability of GLP-2 to regulate intestinal permeability, we confirmed and extended previous published data showing that GLP-2 aVected gut growth. We demonstrated that GLP-2 treated mice had increased intestinal weight, mucosal weight, total protein, and longer villi. In addition, our electron microscopy studies showed for the first time that the growth enhancing properties of GLP-2 also applied to individual enterocytes and their microvilli. The protease resistant analogue, h[Gly 2 ]GLP-2, exerted similar and often greater eVects on gut morphology than the native peptide. This may be of therapeutic relevance as it has been shown that rats are less responsive than mice to GLP-2 because of degradation by dipeptidyl peptidase IV. Under the conditions of our experiment, Isc was similar in both controls and GLP-2 treated mice. This result is not inconsistent with previous findings of enhanced expression of glucose transporters 30 as in our study the mucosal buVer did not contain glucose to stimulate Na + absorption via SGLT1 (which would increase Isc).
Decreased ionic permeability does not necessarily indicate similar permeability changes for larger molecules. Consequently, we examined the mucosal-to-serosal flux of Cr-EDTA to assess the eVect of GLP-2 on the uptake of luminally derived material. Because of its small size (molecular weight 360) and lipid insolubility, Cr-EDTA has been used extensively to assess paracellular permeability in patients with intestinal disorders. 32 We observed a similar reduction in the flux of Cr-EDTA (about (1) it is a 44 kDa glycoprotein that under normal circumstances traverses the epithelium via transcytosis; and (2) intact HRP can be conveniently quantified using an enzymatic assay. 25 26 We noted a dramatic diminution (by up to 80%) of transepithelial HRP flux across jejunum from GLP-2 or h[Gly 2 ]GLP-2 treated mice compared with controls, with h[Gly 2 ]GLP-2 being more eVective than GLP-2. A 50% reduction in the area of HRP containing endosomes within enterocytes confirmed that peptide treatment decreased epithelial uptake of this macromolecule. It is possible that the increased length of the cells was responsible for a decreased rate of movement of this large molecule across the tissues. In addition, a longer period for transcytosis would provide increased opportunity for degradation of the protein by lysosomal enzymes.
To determine if the enhanced barrier function was due simply to an increased number of longer and more densely packed enterocytes, additional experiments were carried out in mice treated with h[Gly 2 ]GLP-2 for four and 48 hours when, theoretically, epithelial cell growth would be negligible or minimal. Indeed, we found that there were no significant changes in any of the morphological features at four hours although both enterocyte length and microvillus length were significantly increased by 48 hours. In contrast, tissue conductance was significantly reduced at both four and 48 hours, and the flux of Cr-EDTA was also significantly decreased at both early times. These data indicate a discrepancy between the change in the length of the paracellular pathway and its permeability, and suggest that GLP-2 acts on elements involved in maintaining the integrity of epithelial tight junctions. Furthermore, the flux of HRP was more dramatically diminished (by >50% at four hours) indicating the ability of h[Gly 2 ]GLP-2 to rapidly influence epithelial cell function. As four hours was the earliest time point we examined, we do not know if eVects may occur even earlier. However, direct addition of GLP-2 to tissues in Ussing chambers did not result in any significant changes in Isc or conductance within 90 minutes. Collectively, our data imply that GLP-2 and h[Gly 2 ]GLP-2 rapidly and eVectively reduce paracellular permeability in the small intestine and so would be expected to retard the uptake of small, luminally derived proinflammatory molecules of comparable size into the mucosa. In addition, decreased uptake of HRP suggests that GLP-2 would reduce uptake of foreign protein antigens with immunogenic properties.
Thus our data have shown that GLP-2 and h[Gly 2 ]GLP-2 are not only growth promoting agents for intestinal mucosa but also enhance gut epithelial barrier function. This latter finding has clear implications for innate immunity. While the cellular and molecular mechanisms underlying these properties of GLP-2 remain to be defined, a number of scenarios can be postulated. Firstly, GLP-2 increases the rate of crypt cell proliferation and reduces apoptosis, 28 and one group has reported 33 that crypt cell apoptosis leads to increased permeability in murine epithelial cells. Modulation of tight junction form and function would aVect paracellular permeability. Secondly, villus elongation could physically restrict access to the crypt region where tight junctions are more leaky than those present in the villus. 34 In addition, rearrangement of the epithelial cytoskeleton (mircofilaments and microtubules) would affect the paracellular and transcellular permeation pathways. 35 Further experiments in progress suggest that the mechanism involves several pathways. As a caveat to this discussion we would highlight that GLP-2 does not aVect muscle thickness (Benjamin et al, unpublished data and Drucker and colleagues 22 ), and consequently muscular changes cannot be responsible for altered flux across the full thickness intestinal segments used in this study. Our data with Cr-EDTA and HRP suggest that GLP-2 treatment aVects both paracellular and transcellular permeability and eVectively retards the entry of bioactive immunogenic molecules, of a range of sizes, into the mucosa. Therefore, the recently reported beneficial eVects of h[Gly 2 ]GLP-2 in a mouse model of colitis 36 may be due, at least in part, to enhanced barrier function.
In summary, we have provided clear evidence that GLP-2 and a protease resistant analogue enhance the barrier function of the intestinal epithelium. By virtue of its intestinotrophic properties, therapeutic uses for GLP-2 have been suggested for conditions that result in villus atrophy such as short bowel syndrome 37 and consequent to total parenteral nutrition. 38 Furthermore, the research findings presented here underscore the potential role of GLP-2 therapy in combatting inflammatory disorders that are characterised by disruption of the normal barrier function of the epithelial lining of the small intestine.
